Esperion Therapeutics Inc (NASDAQ:ESPR) was the recipient of some unusual options trading on Friday. Stock investors purchased 2,377 put options on the stock. This represents an increase of approximately 2,081% compared to the average daily volume of 109 put options.

Shares of Esperion Therapeutics (NASDAQ:ESPR) opened at $73.26 on Monday. The company has a market capitalization of $1,880.00, a price-to-earnings ratio of -10.68 and a beta of 2.73. Esperion Therapeutics has a 52 week low of $10.71 and a 52 week high of $74.95.

Esperion Therapeutics (NASDAQ:ESPR) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.86) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.07). During the same quarter in the prior year, the business earned ($0.77) earnings per share. equities research analysts anticipate that Esperion Therapeutics will post -7.36 EPS for the current year.

Several equities analysts have issued reports on ESPR shares. Bank of America upgraded Esperion Therapeutics from a “neutral” rating to a “buy” rating and set a $76.00 price objective for the company in a research report on Friday, January 5th. BidaskClub upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, December 16th. Northland Securities reiterated a “buy” rating and issued a $72.00 price objective on shares of Esperion Therapeutics in a research report on Friday, November 10th. Stifel Nicolaus reiterated a “buy” rating and issued a $70.00 price objective on shares of Esperion Therapeutics in a research report on Wednesday, October 4th. Finally, Chardan Capital lifted their price objective on Esperion Therapeutics from $20.00 to $75.00 and gave the company a “neutral” rating in a research report on Wednesday, December 6th. Six research analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. Esperion Therapeutics has an average rating of “Buy” and an average price target of $62.08.

In other Esperion Therapeutics news, Director Nicole Vitullo sold 9,326 shares of Esperion Therapeutics stock in a transaction on Wednesday, December 6th. The stock was sold at an average price of $53.85, for a total value of $502,205.10. Following the completion of the transaction, the director now owns 2,472 shares in the company, valued at approximately $133,117.20. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 32.50% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ESPR. Schwab Charles Investment Management Inc. increased its stake in shares of Esperion Therapeutics by 23.8% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 68,275 shares of the biopharmaceutical company’s stock valued at $3,160,000 after buying an additional 13,146 shares during the period. SG Americas Securities LLC increased its stake in shares of Esperion Therapeutics by 74.5% in the 2nd quarter. SG Americas Securities LLC now owns 7,008 shares of the biopharmaceutical company’s stock valued at $324,000 after buying an additional 2,991 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Esperion Therapeutics by 9.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 114,853 shares of the biopharmaceutical company’s stock valued at $5,315,000 after buying an additional 10,250 shares during the period. Neuberger Berman Group LLC acquired a new stake in shares of Esperion Therapeutics in the 2nd quarter valued at $764,000. Finally, Swiss National Bank increased its stake in shares of Esperion Therapeutics by 18.5% in the 2nd quarter. Swiss National Bank now owns 26,300 shares of the biopharmaceutical company’s stock valued at $1,217,000 after buying an additional 4,100 shares during the period. 92.24% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Esperion Therapeutics Target of Unusually High Options Trading (ESPR)” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/15/esperion-therapeutics-target-of-unusually-high-options-trading-espr.html.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.